Advertisement

Topics

FDA Grants Orphan Drug Designation to Poseida’s P-BCMA-101 for the Treatment of Multiple Myeloma

10:45 EDT 13 May 2019 | Speciality Pharma Journal

SAN DIEGO, May 13, 2019 (GLOBE NEWSWIRE) — Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create life-saving therapeutics, today announced the United States Food and Drug Administration (FDA) has granted orphan drug designation to P-BCMA-101 for the treatment of relapsed and/or refractory multiple myeloma. P-BCMA-101 is an autologous …

Original Article: FDA Grants Orphan Drug Designation to Poseida’s P-BCMA-101 for the Treatment of Multiple Myeloma

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Orphan Drug Designation to Poseida’s P-BCMA-101 for the Treatment of Multiple Myeloma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...